Protalix Bio Therapeutics
Protalix Bio Therapeutics (PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. This stock is trading up 1.9% to $5.76 in recent trading.
Today's Range: $5.60-$5.8152-Week Range: $4.06-$7.70 Volume: 196,000 Three-Month Average Volume: 824,029 From a technical perspective, PLX is bouncing off some near-term support at around $5.56 with low volume. For the past few weeks, shares of PLX have found some decent buying interest whenever this stock has pulled back under $5.60. >>22 Biopharma Stocks With Breakout Potential in 2012 Traders should now look for long-biased trades once PLX clears both its 200-day at $5.96 and its 50-day at $6.12 with high volume. Look for a sustained move or close above those levels with volume that's near or above 824,029 shares. A move above those levels will also push PLX above some near-term breakout levels at $5.87 to $5.96, which is bullish technical price action. If we get that action soon, then PLX has a great chance of re-filing a previous gap-down from June and trading up to $6.80 to $6.95, or possibly even $7.70. Keep in mind that those targets will only have a chance of getting hit if PLX can sustains a high-volume trend over both its 200-day and 50-day moving averages. To see more stocks under-$10 that are making notable moves higher today, check out the Stocks Under-$10 Moving Higher portfolio on Stockpickr. -- Written by Roberto Pedone in Winderemere, Fla.
Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV